Joining Hands with PwC, to Provide Early Cancer Detection Test via Employee Benefit Platform
Take2 Health has reached a collaboration with PwC that starting from 2 December 2021, PwC employees can enjoy the privileged price for taking the Take2 Prophecy™ Test for Nasopharyngeal Cancer in designated medical service providers through their corporate welfare platform PwC Wellness Reimagined.
PwC Wellness Reimagined is a corporate welfare platform exclusively designed for all PwC employees in Hong Kong, Macau and mainland China, which integrates diversified benefit items ranging from digital products, educational courses, entertainment to healthcare. Take2 Health will continue to join hands with the world’s leading companies and provide early cancer detection tests for industry professionals, enabling them to monitor their wellbeing more thoroughly.
More Latest News
Nasopharyngeal Cancer Screening Results May “Predict” Development of Related Cancer and Improve Early Diagnosis, CUHK Study Finds
A recent study conducted by The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) has shown that individuals with detectable plasma Epstein–Barr virus (EBV) DNA but without an immediately identifiable nasopharyngeal cancer (NPC) after further investigation with nasal endoscopic examination and magnetic resonance imaging (MRI), have a higher risk of developing NPC in 3 to 5 years, up to 17 times higher than those tested “negative” in the test. The non-invasive liquid biopsy techniques not only could be used for early cancer detection but may also indicate the risk for future cancer development.
Promoting NPC Awareness across the City
Joining Hands with Bowtie to Sponsor the Take2 Prophecy™ Test for Nasopharyngeal Cancer to the High-risk Group
Awarded as The Company with the Most Investment Potential & The Top Breakthrough Innovation
Take2 Health are privileged to have participated in the first ZAODX World Conference on Early Detection of Cancer, and are very honoured to be awarded as The Company with the Most Investment Potential (金篩獎‧最具投資價值潛力企業) as well as The Top Breakthrough Innovation (金篩獎‧突破性創新獎)
